IBD Exposure to anti-TNF agents in utero: controlling health risks

C.J. van der Woude; Shannon Kanis

doi:10.1038/nrgastro.2016.94

IBD Exposure to anti-TNF agents in utero: controlling health risks

C.J. van der Woude, Shannon Kanis

Gastroenterology & Hepatology

Research output: Contribution to journal › Article › Academic › peer-review

5 Citations (Scopus)

Abstract

A recent study reports on drug clearance in newborn babies after in utero exposure to anti-TNF antibodies, infliximab and adalimumab. As women with IBD are increasingly exposed to these drugs due to changing treatment paradigms and earlier diagnosis, this commentary explores these clinically important results.

Original language	Undefined/Unknown
Pages (from-to)	387-+
Journal	Nature reviews - gastroenterology & hepatology
Volume	13
Issue number	7
DOIs	https://doi.org/10.1038/nrgastro.2016.94
Publication status	Published - 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/nrgastro.2016.94

http://hdl.handle.net/1765/93321

Cite this

@article{ae5734d2575b4dea8bcb127ad59361f6,

title = "IBD Exposure to anti-TNF agents in utero: controlling health risks",

abstract = "A recent study reports on drug clearance in newborn babies after in utero exposure to anti-TNF antibodies, infliximab and adalimumab. As women with IBD are increasingly exposed to these drugs due to changing treatment paradigms and earlier diagnosis, this commentary explores these clinically important results.",

author = "{van der Woude}, C.J. and Shannon Kanis",

year = "2016",

doi = "10.1038/nrgastro.2016.94",

language = "Undefined/Unknown",

volume = "13",

pages = "387--+",

number = "7",

}

TY - JOUR

T1 - IBD Exposure to anti-TNF agents in utero: controlling health risks

AU - van der Woude, C.J.

AU - Kanis, Shannon

PY - 2016

Y1 - 2016

N2 - A recent study reports on drug clearance in newborn babies after in utero exposure to anti-TNF antibodies, infliximab and adalimumab. As women with IBD are increasingly exposed to these drugs due to changing treatment paradigms and earlier diagnosis, this commentary explores these clinically important results.

AB - A recent study reports on drug clearance in newborn babies after in utero exposure to anti-TNF antibodies, infliximab and adalimumab. As women with IBD are increasingly exposed to these drugs due to changing treatment paradigms and earlier diagnosis, this commentary explores these clinically important results.

U2 - 10.1038/nrgastro.2016.94

DO - 10.1038/nrgastro.2016.94

M3 - Article

VL - 13

SP - 387-+

IS - 7

ER -